Trial Profile
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Zanidatamab zovodotin (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Anal cancer; Biliary cancer; Bladder cancer; Cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Gynaecological cancer; HER2 positive breast cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Zymeworks
- 07 Dec 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2025.
- 15 Oct 2023 According to Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023, based on these results, 2.5 mg/kg Q3W regimen was chosen as the RD.
- 09 May 2023 Status changed from recruiting to active, no longer recruiting.